Physician profile
Hui Guan
NPI 1992729321
$7,730.00
in general payments reported to CMS, 2019-2025
28 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $869 · 2021: $1,405 · 2022: $1,428 · 2023: $1,177 · 2024: $741 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.60 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,658.52 | 2019-2025 | Aveir, Jot Dx |
| Astrazeneca Pharmaceuticals LP | $1,372.54 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $1,080.21 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $636.86 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $352.05 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.91 | 2019-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $305.48 | 2022-2025 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $248.48 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $223.17 | 2019-2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $207.77 | 2020-2022 | |
| Pfizer INC. | $199.78 | 2019-2024 | |
| Amgen INC. | $193.79 | 2019-2023 | Repatha |
| Imperative Care, INC | $145.15 | 2025 | Zoom 88-T Large Distal Platform |
| Novo Nordisk INC | $125.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.16 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $76.79 | 2025 | Shingrix |
| Cvrx, INC. | $73.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $65.30 | 2019 | |
| Boston Scientific Corporation | $63.50 | 2019-2020 | |
| Amarin Pharma, INC. | $56.37 | 2019-2020 | |
| Biotronik INC. | $50.32 | 2021 | |
| Scpharmaceuticals INC. | $30.49 | 2025 | |
| Abbvie INC. | $30.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.05 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.55 | 2019 | |
| Bardy Diagnostics, INC. | $21.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.78 | 2021 | |
| Astellas Pharma US INC | $16.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Guan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.